Brevan Howard Capital Management
TSHA icon

Brevan Howard Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Brevan Howard Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-46,643
Closed -$153K – 2283
2025
Q3 		$153K Buy
+46,643
New +$132K ﹤0.01% 1811
2024
Q2 		– Sell
-172,769
Closed -$496K – 1404
2024
Q1 		$496K Buy
+172,769
New +$360K ﹤0.01% 467

Other funds holding TSHA

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Brevan Howard Capital Management's TSHA Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 46,643 shares — an estimated $153K sold.

Brevan Howard Capital Management first reported a position in TSHA in Q1 2024 and held it in 2 quarters. The position peaked at $496K in Q1 2024. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 46,643 Taysha Gene Therapies shares in Q4 2025, an estimated $153K.
  • Brevan Howard Capital Management first reported a position in Taysha Gene Therapies in Q1 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's Taysha Gene Therapies position peaked at $496K in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.